Institute for Infection and Immunity, St George's, University of London, London, SW17 ORE, UK.
Molecular and Clinical Sciences Research Institute, St George's, University of London, London, SW17 ORE, UK.
Rheumatol Int. 2018 Aug;38(8):1429-1435. doi: 10.1007/s00296-018-4085-2. Epub 2018 Jun 23.
Increasing evidence supports the role of central sensitisation in osteoarthritis (OA) pain. In this study, we used neuroimaging to compare pain-processing regions of the brain in participants with and without hand OA. We then assessed for volumetric changes in these brain regions following treatment with centrally acting analgesics.
Participants with hand OA (n = 28) underwent T1-weighted MRI of the brain before and after 12 weeks of treatment with pregabalin, duloxetine or placebo. Grey matter volume in the anterior cingulate cortex (ACC), insular cortex and thalamus was compared to non-OA control subjects (n = 11) using FreeSurfer regional volumetric analysis and voxel-based morphometry, and evaluated for differences pre- and post-treatment.
Relative to non-OA controls, hand OA participants had areas of reduced grey matter volume in the ACC at baseline (p = 0.007). Regional volumetric differences in the ACC persisted after 13 weeks' treatment with pregabalin or duloxetine (p = 0.004) with no significant differences between treatment cohorts, despite improvements in NRS pain scores for pregabalin (p = 0.005) and duloxetine (p = 0.050). The ACC grey matter changes persisted despite a significant improvement in pain in the pregabalin and duloxetine groups vs. placebo. No structural differences were observed in the insular cortex or thalamus at baseline or following treatment.
Our study found evidence of reduced ACC grey matter volume in participants with hand arthritis that persisted after treatment with centrally acting analgesics pregabalin and duloxetine, respectively. The sustained changes observed in the ACC in our study could reflect the relatively short duration of treatment, or that the differences observed are irreversible volume changes due to chronic pain that are established over time.
越来越多的证据支持中枢敏化在骨关节炎(OA)疼痛中的作用。在这项研究中,我们使用神经影像学比较了有和没有手部 OA 的参与者的大脑疼痛处理区域。然后,我们评估了在使用中枢作用镇痛药治疗后这些大脑区域的体积变化。
有手部 OA(n=28)的参与者在接受普瑞巴林、度洛西汀或安慰剂治疗 12 周前后接受了大脑 T1 加权 MRI。使用 FreeSurfer 区域容积分析和体素形态计量学比较了前扣带皮层(ACC)、岛叶和丘脑的灰质体积,并评估了治疗前后的差异。
与非 OA 对照组相比,手部 OA 参与者在基线时有 ACC 灰质体积减少的区域(p=0.007)。在接受普瑞巴林或度洛西汀治疗 13 周后,ACC 的区域容积差异仍然存在(p=0.004),尽管普瑞巴林(p=0.005)和度洛西汀(p=0.050)的 NRS 疼痛评分有所改善,但治疗组之间没有显著差异。尽管普瑞巴林和度洛西汀组的疼痛明显改善,但 ACC 灰质变化仍然存在。在基线或治疗后,均未观察到岛叶或丘脑的结构差异。
我们的研究发现,手部关节炎患者的 ACC 灰质体积减少,分别在接受中枢作用镇痛药普瑞巴林和度洛西汀治疗后仍然存在。我们研究中在 ACC 观察到的持续变化可能反映了治疗的相对短暂性,或者观察到的差异是由于慢性疼痛而导致的不可逆转的体积变化,这些变化是随着时间的推移而建立的。